Skip to main content
Account

Table 4 Latency after intake of any symptomatic therapy, among patients who were treated with analgesics (i.e., users)

From: Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting

 

T0

T6

T12

T18

Latency time (h)

Mean ± SD

5.9 ± 0.4

2.9 ± 1.5

2.1 ± 1.4

2.0 ± 1.5

Median (q1–q3)

6 (6–6)

3 (2–4)

2 (1–3)

1.5 (1–2)

Range

95% CI

Users

4–6

5.4–6.5

47

1–6

2.5–3.4

46

1–6

1.8–2.5

47

1–6

1.7–2.4

44

p values from HGLM and pairwise comparisons

 

p for overall difference

T6 vs. T0

T12 vs. T6

T18 vs. T12

p for trend

Latency time (h)

<0.001

<0.001

0.001

0.654

<0.001